Literature DB >> 15770650

Multifocal motor neuropathy: current concepts and controversies.

Eduardo Nobile-Orazio1, Alberto Cappellari, Alberto Priori.   

Abstract

Multifocal motor neuropathy (MMN) is now a well-defined purely motor multineuropathy characterized by the presence of multifocal partial motor conduction blocks (CB), frequent association with anti-GM1 IgM antibodies, and usually a good response to high-dose intravenous immunoglobulin (IVIg) therapy. However, several issues remain to be clarified in the diagnosis, pathogenesis, and therapy of this condition including its nosological position and its relation to other chronic dysimmune neuropathies; the degree of CB necessary for the diagnosis of MMN; the existence of an axonal form of MMN; the pathophysiological basis of CB; the pathogenetic role of antiganglioside antibodies; the mechanism of action of IVIg treatments in MMN and the most effective regimen; and the treatment to be used in unresponsive patients. These issues are addressed in this review of the main clinical, electrophysiological, immunological, and therapeutic features of this neuropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770650     DOI: 10.1002/mus.20296

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

Review 1.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 2.  Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home.

Authors:  Mary Lucas; Ken Hugh-Jones; Angela Welby; Siraj Misbah; Peter Spaeth; Helen Chapel
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

4.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

Authors:  F Galban-Horcajo; A M Fitzpatrick; A J Hutton; S M Dunn; G Kalna; K M Brennan; S Rinaldi; R K Yu; C S Goodyear; H J Willison
Journal:  Eur J Neurol       Date:  2012-06-22       Impact factor: 6.089

Review 5.  Intravenous immunoglobulin in therapy of peripheral neuropathy.

Authors:  Alexander Gorshtein; Yair Levy
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

6.  High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy.

Authors:  Eduardo Nobile-Orazio; Dario Cocito; Chiara Briani; Rosaria Plasmati; Angelo Schenone; Francesca Gallia; Ivan Marjanovic; Anna Lotti Suffredini
Journal:  Neurol Sci       Date:  2017-01-31       Impact factor: 3.307

7.  A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis.

Authors:  Giuseppe Paolazzi; Susanna Peccatori; Francesco P Cavatorta; Alberto Morini
Journal:  Clin Rheumatol       Date:  2009-04-07       Impact factor: 2.980

8.  Electrophysiological predictors of steroid-responsiveness in chronic inflammatory demyelinating polyneuropathy.

Authors:  Y A Rajabally; M Narasimhan; G Chavada
Journal:  J Neurol       Date:  2008-04-30       Impact factor: 4.849

Review 9.  Subcutaneous immunoglobulin: opportunities and outlook.

Authors:  S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

10.  Wartenberg's migrant sensory neuritis: a prospective follow-up study.

Authors:  Abraham C J Stork; Marjon F G van der Meulen; W-Ludo van der Pol; Alexander F J E Vrancken; Hessel Franssen; Nicolette C Notermans
Journal:  J Neurol       Date:  2010-03-31       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.